Curcumin vs Omega-3: Anti-Inflammatory Supplements Compared

Omega-3s have stronger clinical evidence (REDUCE-IT, VITAL, STRENGTH) and reliable bioavailability. Curcumin has anti-inflammatory mechanism evidence but poor bioavailability (<1%) and smaller trials. For inflammation, omega-3s have the stronger evidence base.

Yes — no adverse interactions are known, and they work through different pathways (omega-3: SPMs; curcumin: NF-κB). They may be complementary. Use enhanced curcumin forms. Consult your healthcare provider before combining.

Curcumin has <1% oral bioavailability due to poor solubility, rapid metabolism, and GI degradation. Enhanced formulations (phytosome, nano) improve this 7-46x, but most positive trials used specific proprietary forms.

REDUCE-IT (n=8,179) showed 4g/day EPA reduced cardiovascular events by 25%. Omega-3s also reduce triglycerides 15-30% and have FDA-approved prescription forms. It's among the strongest supplement trial evidence.

Meriva (curcumin phytosome) improved osteoarthritis symptoms comparably to NSAIDs in an 8-month trial with fewer side effects. Results depend on using bioavailability-enhanced forms — standard curcumin has limited absorption.

Omega-3: 2-4 g/day combined EPA+DHA for clinical triglyceride reduction. Curcumin: 500-2,000 mg/day of enhanced formulations (with piperine or phytosome). Doses and forms differ significantly.

Both are generally safe. Omega-3s may have a mild blood-thinning effect at high doses. Curcumin may interact with anticoagulants and CYP enzymes. Neither has serious adverse events at standard doses in healthy people.

Enhanced forms (phytosome, nano, piperine-combined) improve bioavailability 7-46x over standard curcumin. Most positive clinical trials used specific proprietary forms (e.g., Meriva, BCM-95). Form matters greatly with curcumin.

Omega-3s have strong cardiovascular evidence (REDUCE-IT: 25% event reduction with EPA). Curcumin has limited cardiovascular trial data. For heart health, omega-3s are far better supported.

Despite over 12,000 published curcumin studies, no curcumin compound has been approved as a drug by any major regulatory agency. Curcumin shows activity in many lab assays, but Nelson et al. (2017) classified it as a PAINS compound with non-specific activity. Clinical cancer evidence is weak.

EPA-dominant omega-3 formulations showed antidepressant effects in meta-analysis, with effect sizes comparable to standard antidepressants. Curcumin has some depression evidence but smaller. Omega-3s (EPA) have the stronger data.

No. ALA from plant sources converts to EPA/DHA at only 5-10% efficiency, making it a poor substitute for fish or algal oil. Algal oil is the vegan equivalent with direct DHA/EPA.

Standard curcumin is cheap, but enhanced forms (phytosome) cost more. Omega-3 fish oil is moderately priced; prescription EPA is pricier. At effective doses, costs are comparable, but omega-3s deliver more evidence per dollar.

Omega-3 effects on triglycerides appear within weeks; cardiovascular outcomes in trials measured over years. Curcumin's anti-inflammatory effects (with enhanced forms) may appear in 4-8 weeks. Neither works overnight.

Meriva curcumin improved osteoarthritis symptoms comparably to NSAIDs in one trial with fewer side effects. Omega-3s reduce inflammation but aren't direct NSAID replacements. Neither should replace prescribed medications without medical supervision.